Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018' outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 6, 1 and 4 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Musculoskeletal Disorders, Dermatology, Gastrointestinal and Respiratory which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Colorectal Cancer, Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Actinic (Solar) Keratosis, Allergic Rhinitis, Arthritis, Autoimmune Disorders, Breast Cancer, Crohn's Disease (Regional Enteritis), Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sarcomas, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ulcerative Colitis and Warts.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018' outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 6, 1 and 4 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Musculoskeletal Disorders, Dermatology, Gastrointestinal and Respiratory which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Colorectal Cancer, Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Actinic (Solar) Keratosis, Allergic Rhinitis, Arthritis, Autoimmune Disorders, Breast Cancer, Crohn's Disease (Regional Enteritis), Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sarcomas, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ulcerative Colitis and Warts.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
AstraZeneca Plc
BioNTech AG
Celgene Corp
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
Idera Pharmaceuticals Inc
Janus Biotherapeutics Inc
MedImmune LLC
Nektar Therapeutics
Pfizer Inc
Vivelix Pharmaceuticals Ltd
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bazlitoran sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1508052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + MEDI-9197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DV-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMO-9200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JB-6121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-9197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
motolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-262 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSLV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-1463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Apr 15, 2018: Nektar Therapeutics Presents New Preclinical Data on NKTR-262 at the American Association for Cancer Research (AACR) Annual Meeting 2018
Apr 11, 2018: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting
Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus
Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination
May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference
Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study
Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia
Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting
May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors
Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer
Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma
Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
AstraZeneca Plc
BioNTech AG
Celgene Corp
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
Idera Pharmaceuticals Inc
Janus Biotherapeutics Inc
MedImmune LLC
Nektar Therapeutics
Pfizer Inc
Vivelix Pharmaceuticals Ltd
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
854-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bazlitoran sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1508052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + MEDI-9197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DV-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9688 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMO-9200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JB-6121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-9197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
motolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-262 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSLV-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-1463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Apr 15, 2018: Nektar Therapeutics Presents New Preclinical Data on NKTR-262 at the American Association for Cancer Research (AACR) Annual Meeting 2018
Apr 11, 2018: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting
Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus
Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination
May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference
Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study
Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia
Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting
May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors
Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer
Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma
Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Dynavax Technologies Corp, H1 2018
Pipeline by Eisai Co Ltd, H1 2018
Pipeline by Galderma SA, H1 2018
Pipeline by Gilead Sciences Inc, H1 2018
Pipeline by Idera Pharmaceuticals Inc, H1 2018
Pipeline by Janus Biotherapeutics Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Nektar Therapeutics, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Vivelix Pharmaceuticals Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by BioNTech AG, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Dynavax Technologies Corp, H1 2018
Pipeline by Eisai Co Ltd, H1 2018
Pipeline by Galderma SA, H1 2018
Pipeline by Gilead Sciences Inc, H1 2018
Pipeline by Idera Pharmaceuticals Inc, H1 2018
Pipeline by Janus Biotherapeutics Inc, H1 2018
Pipeline by MedImmune LLC, H1 2018
Pipeline by Nektar Therapeutics, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Vivelix Pharmaceuticals Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AstraZeneca Plc
BioNTech AG
Celgene Corp
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
Idera Pharmaceuticals Inc
Janus Biotherapeutics Inc
MedImmune LLC
Nektar Therapeutics
Pfizer Inc
Vivelix Pharmaceuticals Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AstraZeneca Plc
BioNTech AG
Celgene Corp
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
Idera Pharmaceuticals Inc
Janus Biotherapeutics Inc
MedImmune LLC
Nektar Therapeutics
Pfizer Inc
Vivelix Pharmaceuticals Ltd
